Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. The growth is primarily attributed to approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. This milestone underscores the commercial potential of TONMYA and marks a pivotal moment for the company as it establishes a foothold in the central nervous system (CNS) market.
During the quarter, TONMYA recorded 12,592 total prescriptions, a 100% sequential increase. New patient prescriptions rose 36%, while refills surged 207%, indicating strong patient adherence and growing acceptance among physicians. The drug currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027, further broadening patient access.
The robust sales performance is particularly noteworthy given the competitive landscape and the historical challenges in treating fibromyalgia. TONMYA is the first new treatment for the condition in more than 15 years, offering a novel sublingual formulation of cyclobenzaprine that aims to improve efficacy and tolerability. The positive reception suggests a significant unmet medical need that Tonix is now addressing.
Beyond TONMYA, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These programs highlight Tonix's commitment to addressing high unmet needs in CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This runway provides the company with the flexibility to execute its commercial strategy and advance its pipeline.
The implications of this announcement are significant for Tonix and the broader pharmaceutical industry. The strong launch of TONMYA not only validates the company's commercial infrastructure but also positions it for sustained growth. The expansion of coverage and increasing prescription trends suggest a favorable trajectory. Moreover, the advancement of pipeline candidates diversifies Tonix's portfolio and reduces reliance on a single product.
Investors and stakeholders will be watching closely as Tonix navigates the competitive landscape and continues to execute on its strategic initiatives. The company's ability to sustain this momentum will be crucial in establishing TONMYA as a standard of care for fibromyalgia and in realizing the potential of its other promising therapies. For more information on Tonix Pharmaceuticals, visit their newsroom at https://nnw.fm/TNXP.
